Cyclobenzaprine

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 338 publications

Sublingual cyclobenzaprine (Tonmya) for fibromyalgia.

Sublingual cyclobenzaprine (Tonmya) for fibromyalgia.

Journal: The Medical letter on drugs and therapeutics
Published: January 08, 2026

Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses.

Current evidence on TNX-102 SL (cyclobenzaprine HCl sublingual) for fibromyalgia: strengths, limitations, and emerging hypotheses.

Journal: Clinical rheumatology
Published: December 01, 2025

Efficacy and safety of TNX-102 SL in patients with fibromyalgia: a systematic review and meta-analysis.

Efficacy and safety of TNX-102 SL in patients with fibromyalgia: a systematic review and meta-analysis.

Journal: Pain management
Published: October 06, 2025

Sublingual Cyclobenzaprine: First Approval.

Sublingual Cyclobenzaprine: First Approval.

Journal: Clinical drug investigation
Published: October 06, 2025

Paper-based reaction devices as accelerated platforms in forced degradation studies.

Paper-based reaction devices as accelerated platforms in forced degradation studies.

Journal: Journal of pharmaceutical sciences
Published: September 29, 2025

Tonmya (cyclobenzaprine hydrochloride sublingual tablets): first FDA-approved therapy for fibromyalgia in over 15 years.

Tonmya (cyclobenzaprine hydrochloride sublingual tablets): first FDA-approved therapy for fibromyalgia in over 15 years.

Journal: Annals of medicine and surgery (2012)
Published: September 10, 2025

Short-term efficacy and safety of sublingual cyclobenzaprine for fibromyalgia: A systematic review and meta-analysis.

Short-term efficacy and safety of sublingual cyclobenzaprine for fibromyalgia: A systematic review and meta-analysis.

Journal: Clinical rheumatology
Published: September 09, 2025

Efficacy and safety of interventions for Fibromyalgia syndrome comorbid with Irritable bowel syndrome: systematic review.

Efficacy and safety of interventions for Fibromyalgia syndrome comorbid with Irritable bowel syndrome: systematic review.

Journal: Clinical rheumatology
Published: August 21, 2025

Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug-drug interactions.

Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug-drug interactions.

Journal: Journal of opioid management
Published: July 30, 2025

Analytical green star area (AGSA) as a new assessment tool for the electrochemical determination of cyclobenzaprine hydrochloride in wastewater samples using recycled graphite-modified nitrogen-doped CQDs.

Analytical green star area (AGSA) as a new assessment tool for the electrochemical determination of cyclobenzaprine hydrochloride in wastewater samples using recycled graphite-modified nitrogen-doped CQDs.

Journal: RSC advances
Published: July 08, 2025

Ketamine Use in a Laboring Mother With Type 4 Ehlers-Danlos Syndrome, a Family History of Malignant Hyperthermia, and Opioid-Induced Seizures.

Ketamine Use in a Laboring Mother With Type 4 Ehlers-Danlos Syndrome, a Family History of Malignant Hyperthermia, and Opioid-Induced Seizures.

Journal: Cureus
Published: July 07, 2025

The impact of tizanidine, thiocolchicoside, and cyclobenzaprine on vascular function in ovariectomized rats.

The impact of tizanidine, thiocolchicoside, and cyclobenzaprine on vascular function in ovariectomized rats.

Journal: Turkish journal of medical sciences
Published: June 25, 2025
Showing 1-12 of 338

Last Updated: 02/24/2026